

## Registered Reports: Guidelines for Authors

Revised March 2018

*eNeuro*, an open-access journal from the Society for Neuroscience, publishes high-quality, broad-based, peer-reviewed research focused solely on the field of neuroscience. *eNeuro* embodies an emerging scientific vision that offers a new experience for authors and readers, all in support of SfN's mission to advance understanding of the brain and nervous system.

**eNeuro is indexed** by Scopus, EMBASE, PubMed, PubMed Central, and Web of Science/ESCI.


Registered Reports are a form of empirical article in which the methods and proposed analyses are pre-registered and reviewed prior to research being conducted. High quality protocols are then provisionally accepted for publication before data collection commences. This format is designed to minimize bias in deductive science, while also allowing the flexibility to conduct exploratory (unregistered) analyses and report serendipitous findings.

The cornerstone of the Registered Reports format is that a significant part of the manuscript will be assessed prior to data collection, with the highest quality submissions accepted in advance. Initial submissions will include a description of the key research question and background literature, hypotheses, experimental procedures, analysis pipeline, a statistical power analysis (or Bayesian equivalent), and pilot data (where applicable).

Initial submissions will be triaged by an editorial team for high scientific significance. Those that pass triage will then be sent for in-depth peer review (Stage 1). Following review, the article will then be either rejected or accepted in principle for publication. Following in principle acceptance (IPA), the authors will then proceed to conduct the study, adhering exactly to the peer-reviewed procedures. When the study is complete the authors will submit their finalized manuscript for re-review (Stage 2) and will upload their raw data, digital study materials, and laboratory log to a publicly accessible file-sharing service. Pending quality checks and a sensible interpretation of the findings, the manuscript will be published regardless of the results.

### Stage 1: Initial Manuscript Submission and Review

Due to the high volume of submissions, the editors will select only the most scientifically promising manuscripts for in-depth peer review. Stage 1 submissions should include the manuscript (details below) and a brief cover letter. Authors are welcome to submit presubmission



enquires for advice on the likely suitability of a study as a Registered Report. However, please note that the editorial board will not agree to send manuscripts for in-depth review until a complete Stage 1 submission has been considered.

### Cover letter

The cover letter should include:

- A brief scientific case for consideration. Authors are encouraged to refer to the likely [replication value](#) of the research. High-value replication studies are welcome in addition to novel studies.
- A statement confirming that all necessary support (e.g. funding, facilities) and approvals (e.g. ethics) are in place for the proposed research. Note that manuscripts will be generally considered only for studies that are able to commence immediately; however authors with alternative plans are

encouraged to contact the central office for advice ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)).

- An anticipated timeline for completing the study if the initial submission is accepted.
- A statement confirming that the authors agree to share their raw data, any digital study materials, and laboratory log for all published results.
- A statement confirming that, following IPA, the authors agree to register their approved protocol on the [Open Science Framework](#) or other recognized repository, either publicly or under private embargo until submission of the Stage 2 manuscript.
- A statement confirming that if the authors later withdraw their paper, they agree to the Journal publishing a short summary of the pre-registered study under a section *Withdrawn Registrations*.

## Manuscript Preparation – Stage 1

Initial Stage 1 submissions should include the following sections:

### *Introduction*

A review of the relevant literature that motivates the research question and a full description of the experimental aims and hypotheses. Please note that following IPA, the Introduction section cannot be altered apart from minor changes, e.g., reflecting novel advances or publications in the field (see below).

### *Material and Methods*

Full description of proposed sample characteristics, including criteria for data inclusion and exclusion (e.g. outlier extraction). Procedures for objectively defining exclusion criteria due to technical errors or for any other reasons must be specified, including details of how and under what conditions data would be replaced.

A description of experimental procedures in sufficient detail to allow another researcher to repeat the methodology exactly, without requiring further information. These procedures must be adhered to exactly in the subsequent experiments or any Stage 2 manuscript can be rejected.

Proposed analysis pipeline, including all preprocessing steps, and a precise description of all planned analyses, including appropriate correction for multiple comparisons. Any covariates or regressors must be stated. Where analysis decisions are contingent on the outcome of prior analyses, these contingencies must be specified and adhered to. Only pre-planned analyses can be reported in the main Results section of Stage 2 submissions. However, unplanned exploratory analyses will be admissible in a separate section of the Results (see below).

Studies involving Neyman-Pearson inference must include a statistical power analysis. Estimated effect sizes should be justified with reference to the existing literature. Since publication bias overinflates published estimates of effect size, power analysis must be based on the *lowest* available or meaningful estimate of the effect size. For frequentist analysis plans, the *a priori* power must be 0.9 or higher for all proposed hypothesis tests. In the case of highly uncertain effect sizes, a variable sample size and interim data analysis is permissible but with inspection points stated in advance, [appropriate Type I error correction for “peeking” employed](#), and a final stopping rule for data collection outlined.

Methods involving Bayesian hypothesis testing are encouraged. For studies involving analyses with Bayes factors, the predictions of the theory must be specified so that a Bayes factor can be calculated. Authors should indicate what distribution will be used to represent the predictions of the theory and how its parameters will be specified. For example, will you use a uniform up to some specified maximum, or a [normal/half-normal to represent a likely effect size](#), or a [JZS/Cauchy with a specified scaling constant](#)? For inference by Bayes factors, authors must be able to guarantee data collection until the Bayes factor is at least 6 times in favor of the experimental hypothesis over the null hypothesis (or *vice versa*). Authors with resource limitations are permitted to specify a maximum feasible sample size at which data collection must cease regardless of the Bayes factor; however to be eligible for advance acceptance this number must be sufficiently large that inconclusive results at this sample size would nevertheless be an important message for the field. For further advice on Bayes factors or Bayesian sampling methods, prospective authors are encouraged to [read this key article by Schönbrodt and Wagenmakers](#) and are invited to contact the *eNeuro* Central Office ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)).

Full descriptions must be provided of any outcome-neutral criteria that must be met for successful testing of the stated hypotheses. Such quality checks might include the absence of floor or ceiling effects in data distributions, positive controls, or other quality checks that are orthogonal to the experimental hypotheses.

Timeline for completion of the study and proposed resubmission date if Stage 1 review is successful. Extensions to this deadline can be negotiated with the action editor.

Any description of prospective methods or analysis plans should be written in future tense.

### *Pilot Data*

Optional. Can be included to establish proof of concept, effect size estimations, or feasibility of proposed methods. Any pilot experiments will be published with the final version of the manuscript and will be clearly distinguished from data obtained for the pre-registered experiment(s).

## Secondary Registrations

eNeuro welcomes submissions proposing secondary analyses of existing data sets, provided authors can supply sufficient evidence (e.g. letter from independent gatekeeper) to confirm that they have had no prior access to the data in question.

Stage 1 submissions that are judged by the editorial board to be of sufficient quality and scientific importance will be sent for in-depth peer review. In considering papers at the registration stage, reviewers will be asked to assess:

1. The importance of the research question(s).
2. The logic, rationale, and plausibility of the proposed hypotheses.
3. The soundness and feasibility of the methodology and analysis pipeline (including statistical power analysis where appropriate).
4. Whether the clarity and degree of methodological detail is sufficient to exactly replicate the proposed experimental procedures and analysis pipeline.
5. Whether the authors have pre-specified sufficient outcome-neutral tests for ensuring that the results obtained are able to test the stated hypotheses, including positive controls and quality checks.

Following Stage 1 peer review, manuscripts will be rejected outright, offered the opportunity to revise, or accepted. Proposals that exceed the highest standards of importance and scientific rigor will be issued an *in principle acceptance* (IPA), indicating that the article will be published pending completion of the approved methods and analytic procedures, passing of all pre-specified quality checks, and a defensible interpretation of the results. Stage 1 protocols are not published following IPA. Instead they are held in reserve by the journal and integrated into a single completed article following approval of the final Stage 2 manuscript.

**Authors are reminded that any deviation from the stated experimental procedures, regardless of how minor it may seem to the authors, could lead to rejection of the manuscript at Stage 2.** In cases where the pre-registered protocol is altered after IPA due to unforeseen circumstances (e.g. change of equipment or unanticipated technical error), the authors must consult the editorial board immediately for advice, and prior to the completion of data collection. Minor changes to the protocol may be permitted according to editorial discretion. In such cases, IPA would be preserved and the deviation reported in the Stage 2 submission. If the authors wish to alter the experimental procedures more substantially following IPA but still wish to publish their article as a Registered Report then the manuscript must be withdrawn and resubmitted as a new Stage 1 submission. Note that registered analyses must be undertaken, but additional unregistered analyses can also be included in a final manuscript (see below).

## Tips for Avoiding Rejection at Stage 1

Many Registered Report submissions are desk rejected at Stage 1, prior to in-depth review, for failing to sufficiently meet the Stage 1 editorial criteria. In many such cases, authors are invited to resubmit once specific shortcomings are addressed, although major problems can lead to outright rejection. To help minimize the chances of authors' submissions being desk rejected, we list below the top ten reasons why Stage 1 submissions are rejected prior to review.

1. Cover letter doesn't make necessary statements concerning ethics, data archiving, and so forth (see above).
2. The protocol contains insufficient methodological detail to enable replication and prevent researcher degrees of freedom. One commonly neglected area is the criteria for excluding data, both at the level of animals/participants and at the level of data within animals/participants. In the interests of clarity, we recommend listing these criteria systematically rather than presenting them in prose.
3. Lack of correspondence between the scientific hypotheses and the pre-registered statistical tests. This is a common problem and severe cases are likely to be desk rejected outright. To maximize clarity of correspondence between predictions and analyses, authors are encouraged to number their hypotheses in the Introduction and then number the proposed analyses in the Methods to make clear which analysis tests which prediction. Ensure also that power analysis, where applicable, is based on the actual test procedures that will be employed to test those 7 hypotheses; e.g. don't propose a power analysis based on an ANOVA but then suggest a linear mixed effects model to test the hypothesis.
4. Power analysis, where applicable, fails to reach the minimum level stated in journal policy.
5. Power analysis is over-optimistic (e.g. based on previous literature but not taking into account publication bias) or insufficiently justified (e.g. based on a single point estimate from a pilot experiment or previous study). Proposals should be powered to detect the smallest effect that is plausible and of theoretical value. Pilot data can help inform this estimate but is unlikely to form an acceptable basis, alone, for choosing the target effect size.

6. Intention to infer support for the null hypothesis from statistically non-significant results, without proposing use of Bayes factors or frequentist equivalence testing.
7. Inclusion of exploratory analyses in the analysis plan. Manuscripts proposing exploratory analyses will usually be desk rejected until such analyses are removed because inclusion of exploratory “plans” at Stage 1 blurs the line between confirmatory and exploratory outcomes at Stage 2. Instead, such analyses can be included at Stage 2 and need not be pre-registered. Under some circumstances, exploratory analyses could be discussed at Stage 1 where they are necessary to justify study variables or procedures that are included in the design exclusively for exploratory analysis.
8. Failure to clearly distinguish work that has already been done from work that is planned. Where a proposal contains a mixture of pilot work that has already been undertaken and a proposal for work not yet undertaken, authors should use the past tense for pilot work but the future tense for the proposed work. At Stage 2, all descriptions shift to past tense.
9. Lack of pre-specified positive controls or other quality checks, or an appropriate justification for their absence (See Stage 1 criterion 5). We recognize that positive controls are not possible with all study designs, in which case authors should discuss why they are not included.
10. Where applicable, lack of power analysis within proposed positive controls that depend on hypothesis testing.

- That, for primary Registered Reports, no data for any pre-registered study (other than pilot data included at Stage 1) was collected prior to the date of IPA. For secondary Registered Reports, authors should confirm that no data (other than pilot data included at Stage 1) was subjected to the pre-registered analyses prior to IPA.

### *Submission of raw data and laboratory log*

Anonymized raw data and digital study materials must be made freely available in a public repository/archive with a link provided within the Stage 2 manuscript. Authors are free to use any repository that renders data and materials freely and publicly accessible and provides a digital object identifier (DOI) to ensure that the data remain persistent, unique and citable. Potential repositories include (but are not limited to), [Figshare](#), [Harvard Dataverse](#), and [Dryad](#). For a comprehensive list of available data repositories, see <http://www.re3data.org/>.

Data files should be appropriately time stamped to show that data was collected after IPA and not before. Other than pre-registered and approved pilot data, no data acquired prior to the date of IPA is admissible in the Stage 2 submission. Raw data must be accompanied by guidance notes, where required, to assist other scientists in replicating the analysis pipeline. Authors are required to upload any relevant analysis scripts and other digital experimental materials that would assist in replication.

Any data or text supporting figures or tables can either be included as [Extended Data](#) that accompanies the paper, or they can be archived together with the data. Please note that the raw data itself should be archived (see above) rather than submitted to the journal as Extended Data.

A basic laboratory log must also be provided outlining the range of dates during which data collection took place. This log should be uploaded to the same public archive as the data and materials.

The Stage 2 manuscript must also contain a link to the registered protocol (deposited following IPA) on the [Open Science Framework](#) or other recognized repository.

### *Background, Rationale, and Methods*

Apart from minor stylistic revisions or the addition of information reflecting the evolution of scientific knowledge, **the Introduction cannot be altered from the approved Stage 1 submission, and the stated hypotheses cannot be amended or appended.** At Stage 2, any description of the rationale or proposed methodology that was written in future tense within the Stage 1 manuscript should be changed to past tense. Any textual changes to the Introduction or Methods (e.g., correction of typographic errors) must be clearly marked in the Stage 2 submission.

## **Stage 2: Full manuscript review**

Once the study is complete, authors prepare and resubmit their manuscript for full review, with the following additions:

### *Cover letter*

The cover letter must confirm:

- That the manuscript includes a link to the public archive containing anonymized study data, digital materials/code and the laboratory log. The cover letter should state the page number in the manuscript that lists the URL.
- That the manuscript contains a link to the approved Stage 1 protocol on the [Open Science Framework](#) or other recognized repository. The cover letter should state the page number in the manuscript that lists the URL.

## Results and Discussion

The outcome of all registered analyses must be reported in the manuscript, except in rare instances where a registered and approved analysis is subsequently shown to be logically flawed or unfounded. In such cases, the authors, reviewers, and editor must agree that a collective error of judgment was made and that the analysis is inappropriate. In such cases the analysis would still be mentioned in the Methods but omitted with justification from the Results.

It is reasonable that authors may wish to include additional analyses that were not included in the registered submission. For instance, a new analytic approach might become available between IPA and Stage 2 review, or a particularly interesting and unexpected finding may emerge. Such analyses are admissible but must be clearly justified in the text, appropriately caveated, and reported in a separate section of the Results titled “*Exploratory analyses.*” Authors should be careful not to base their conclusions entirely on the outcome of statistically significant *post hoc* analyses.

Authors reporting null hypothesis significance tests are required to report exact  $p$  values and effect sizes for all inferential analyses.

The resubmission will most likely be considered by the same reviewers as in Stage 1, but could also be assessed by new reviewers. In considering papers at Stage 2, reviewers will be asked to decide:

1. Whether the data are able to test the authors’ proposed hypotheses by satisfying the approved outcome-neutral conditions (such as quality checks, positive controls)
2. Whether the Introduction, rationale and stated hypotheses are the same as the approved Stage 1 submission (required)
3. Whether the authors adhered precisely to the registered experimental procedures
4. Whether any unregistered *post hoc* analyses added by the authors are justified, methodologically sound, and informative
5. Whether the authors’ conclusions are justified given the data

**Reviewers are informed that editorial decisions will not be based on the perceived importance, novelty or conclusiveness of the results.** Thus while reviewers are free to enter such comments on the record, they will not influence editorial decisions. Reviewers at Stage 2 may suggest that authors report additional *post hoc* tests on their data; however authors are not obliged to do so unless such tests are necessary to satisfy one or more of the Stage 2 review criteria.

## Manuscript withdrawal and Withdrawn Registrations

It is possible that authors with IPA may wish to withdraw their manuscript following or during data collection. Possible reasons could include major technical error, an inability to complete the study due to other unforeseen circumstances, or the desire to submit the results to a different journal. In all such cases, manuscripts can of course be withdrawn at the authors’ discretion. However, *eNeuro* will publicly record each case in a section called *Withdrawn Registrations*. This section will include the authors, proposed title, the Introduction from the approved Stage 1 submission, and brief reason(s) for the failure to complete the study. Partial withdrawals are not possible; i.e. authors cannot publish part of a registered study by selectively withdrawing one of the planned experiments. Such cases must lead to withdrawal of the entire paper. Studies that are not completed by the agreed Stage 2 submission deadline (which can be extended in negotiation with the editorial office) will be considered withdrawn and will be subject to a Withdrawn Registration.

## Incremental Registrations

Authors may add experiments to approved submissions. In such cases the approved Stage 2 manuscript will be accepted for publication, and authors can propose additional experiments for Stage 1 consideration. Where these experiments extend the approved submission (as opposed to being part of new submissions), the editorial team will seek to fast-track the review process. This option may be particularly appropriate where an initial experiment reveals a major serendipitous finding that warrants follow-up within the same paper. In cases where an incremented submission is rejected (at either Stage 1 or 2), authors will retain the option of publishing the most recently approved version of the manuscript. For further advice on specific scenarios for incremental registration, authors are invited to contact the editorial office ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)).

## Checklist for Stage 1 Submissions

Complete details can be found in [Preparing Your Manuscript](#).

### Submission

- The submission may be in PDF, Word, WordPerfect, Postscript, RTF, LaTeX, or Text format.
- The authors and title on the submission form must match those in the separate title page and article files. The article file should not include a title page.
- Preferred reviewing editor(s) must be specified on the submission form. Excluded reviewing editors may also be included.

- Preferred and excluded reviewers may be specified on the submission form.
- Cover letter.
  - Confirms the anticipated timeline of the proposed research, that any necessary resources and approvals are acquired, that the authors agree to deposit the accepted Stage 1 protocol, data, and materials in a public repository, and that the authors agree with the Withdrawn Registration policy.

**Text:**

- No information that would identify any of the authors is present.
- Sections appear in the following order: Introduction, Materials and Methods, and Pilot Data (where applicable).
- All pages are double spaced and numbered.
- No broken URLs are present in the text.
- No footnotes or appendices are present.

**Separate Title Page Includes:**

- Title (50 words maximum).
- Abbreviated title (50 characters maximum).
- Names and affiliations of each author.
- Author contributions.
- Corresponding author's name and email address.
- Funding sources.
- Conflicts of interest (if applicable).
- Acknowledgements.

**Introduction:**

- Word count is  $\leq 750$ .

**Materials and Methods:**

- Sex of subjects is stated (male, female, or of either sex).
- Companies or individuals (with full affiliations) from which unusual materials were obtained are provided.
- Statistical method to be used is stated (descriptive and/or experimental design [random or nonrandom]).
- Descriptions of any proposed methods not yet undertaken are presented in future tense. Descriptions of any methods already undertaken (e.g., in service of pilot/preliminary experiments) are presented in past tense.

**Citations:**

- Proper citation style for *eNeuro* is used.
- A reference is provided for each in-text citation, and *vice versa*.

**Pilot Data:**

- Optional. Can be included to establish proof of concept, effect size estimations, or feasibility of proposed methods. Any pilot experiments will be published with the final version of the manuscript and will be clearly distinguished from data obtained for the pre-registered experiment(s).

## Checklist for Submitting a Stage 2 Registered Report Manuscript

### Submission

- The submission may be either a single PDF file containing all text and figures (pages and figures must be numbered) or multiple files: a manuscript file in Word, WordPerfect, Postscript, RTF, LaTeX, or Text format and each figure in a separate TIFF (300 DPI) or EPS file.
- Source data files essential to the work are included.
- Individual files must always be used for multimedia (.MP4).
- The authors, title and abstract on the submission form must match those in the separate title page and article files. The article file should not include a title page.
- Preferred reviewing editor(s) must be specified on the submission form. Excluded reviewing editors may also be included.
- Preferred and excluded reviewers may be specified on the submission form.
- Cover letter.
  - States the page numbers in the manuscript listing the URLs to the approved Stage 1 protocol and the study data and materials.
  - Confirms that no data for any pre-registered study procedures were collected prior to IPA, and that for any secondary registrations, no pre-registered analyses were conducted prior to IPA.

**Text:**

- No information that would identify any of the authors is present.
- Sections appear in the following order: Abstract, Significance Statement, Introduction, Materials and Methods, Results, Discussion, References, Figure/Table Legends, Figures, and Tables.
- All pages are double spaced and numbered.
- No broken URLs are present in the text.
- No footnotes or appendices are present.
- No reference to supplemental material appears in the text, figures, or tables.

**Separate Title Page Includes:**

- Title (50 words maximum).
- Abbreviated title (50 characters maximum).
- Names and affiliations of each author.
- Author contributions.
- Corresponding author's name and email address.
- Number of figures, tables, and multimedia (separately).
- Number of words for Abstract, Introduction, and Discussion (separately, including any citations).
- Funding sources.
- Conflicts of interest (if applicable).
- Acknowledgements.

# Revising/Finalizing a Manuscript

## Revisions

Detailed instructions for submitting a revised manuscript are included in the decision letter when a manuscript has been judged potentially acceptable for publication.

When submitting a revised manuscript you must:

- Sign the electronic [License to Publish form](#) once the revised manuscript is submitted. A link to the form will be available on the home page of the manuscript submission page for each author, if the corresponding author does not sign for all authors.
- Submit a point-by-point reply to the reviews showing how reviewer concerns were addressed.
- Submit the manuscript text (including tables, if any) in Word, WordPerfect, RTF, LaTeX, or Text format. In addition to a clean copy of the manuscript, you must include a version with all insertions and deletions indicated, so that reviewers can easily see the changes you have made.
- If revisions require adding, deleting, or reordering of figures, tables, or equations, be sure that all in-text references to such items are renumbered as well.
- If the statement “All animal procedures were performed in accordance with the authors’ university animal care committee’s regulations” was used in the materials and methods section to preserve the double-blind process, please be sure to provide the full statement, including the name of the institution in the cover letter so it can be used if the article is accepted.
- Double-check that all in-text citations are in the reference list and that all references on the reference list have at least one corresponding in-text citation. Only published references should appear in the reference list at the end of the paper.
- In the case of “in press” references (i.e., accepted for publication in a specific journal or book), the paper, which must be relevant for reviewers to see in order to make a well-informed evaluation, should be included as an [eNeuro.org](#) SfN Information for Authors separate document text file along with the submitted manuscript. In this case, the authors recognize the loss of anonymity. “Submitted” references should be cited only in text and in the following form:

### Abstract:

- Word count is  $\leq 250$ .
- Species studied is identified in abstract (or title).
- No subheadings are present.

### Significance Statement:

- Word count is  $\leq 120$ .

### Introduction:

- Word count is  $\leq 750$ .

### Materials and Methods:

- Sex of subjects is stated (male, female, or of either sex).
- Companies or individuals (with full affiliations) from which unusual materials were obtained are provided.
- Statistical method used is stated (descriptive and/or experimental design [random or nonrandom]).
- Statistical table is included.
- All methodological descriptions that were prepared in future tense at Stage 1 have been converted to past tense.

### Results:

- Detailed information on each analysis performed is included with specific *p* values.
- The outcomes of confirmatory pre-registered analyses are, in all cases, clearly distinguished from the outcomes of any additional unregistered analyses.

### Discussion:

- Word count is  $\leq 3,000$ .

### Citations:

- Proper citation style for *eNeuro* is used.
- A reference is provided for each in-text citation, and *vice versa*.

### Figures/Multimedia:

- Each illustration is numbered (separate numbering for figures and multimedia).
- Each illustration has a legend and is mentioned in the manuscript.
- All symbols are defined in the caption.

### Tables:

- Each table is numbered and mentioned in the manuscript.
- Tables contain no color or graphics.
- A legend and title are provided for each table.

## License to Publish Form

- Sign the electronic [License to Publish form](#) once the manuscript is submitted. A link to the form will be available on the home page of [eNeuro.msubmit.net](#) for each author, if the corresponding author does not sign for all authors.

(unpublished observations). If the paper is accepted, the authors can then add their names, i.e., (A. B. Smith, C. D. Johnson, and E. Greene, unpublished observations). Submit publication quality digital figures, one per file (see [Multimedia, Figure and Table Guidelines](#)). Check all aspects of illustrations carefully to avoid alterations in the proofs (see also [Proofs](#)). All labels used in a figure should be explained in the legend. Double-check that all labels and symbols mentioned in the figure legend are on the final version of the figure. For questions regarding figure sizing and digital art preparation see [Figures](#).

- Scrutinize your paper at this time for any final corrections in style or substance. Changes at the proof stage are permitted only for corrections of factual errors, printer's errors, or quality of figure reproduction. Other changes may result in a fee.

## Checklist for Submitting a Revised Stage 2 Registered Report Manuscript

Requirements are the same as for initial Stage 2 Registered Report submissions, with the following additions.

### Submission

#### Text/Tables:

- Manuscript file is in Word, WordPerfect, Postscript, RTF, LaTeX, or Text format.
- Separate [Title Page](#) to include any changes on author information, acknowledgements, conflict of interest, or funding sources.
- Individual table files in Word format.
- Each table is in Text format and in black and white; no images or color allowed.

#### Figures/Multimedia:

- Each figure is in a separate TIFF (300 DPI) or EPS file.
- Each figure is in either RGB color mode or Grayscale format.
- A visually captivating image to highlight the published article (landscape format, >1600 pixels wide, EPS or TIFF).
- Individual files are provided for multimedia (MP4).
- A preview image for each video (EPS or TIFF, 300 DPI) best capturing the main point.
- All illustrations submitted at the size they should be published.
- Graphs and figures do not have gridlines or top/right borders.

### License to Publish Form

- Sign the electronic [License to Publish form](#) once the revised manuscript is submitted. A link to the form will be available on the home page of

[eNeuro.msubmit.net](#) for each author, if the corresponding author does not sign for all authors.

## Proofs

Authors should be aware that *eNeuro* limits author alterations in proof. Only corrections of factual errors, copyediting errors, or in the quality of figure reproduction are allowed. This step has been taken to reduce the time required to produce *eNeuro*. All [fees](#) must be paid before a manuscript will be published.

To speed publication of *eNeuro* authors are given 48 hours from receipt of proofs to make and return corrections. Authors should notify *eNeuro*'s central office, [eNeuro@sfn.org](mailto:eNeuro@sfn.org), if the proofs should be sent to an email address other than that of the corresponding author listed on the manuscript. To purchase reprints or to inquire about production charges or invoices, refer to the contact material included with the proofs.

Once a manuscript is accepted, authors' names can only be added, deleted, or altered with the approval of the editors. Requests for changes to the author list will delay publication of a manuscript.